Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02606422 · ClinicalTrials.gov registry record · NA

tDCS Intervention in Primary Progressive Aphasia

A NA study, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
61
Enrollment target

NCT02606422: Completed NA study, sponsored by Johns Hopkins University.

NCT02606422 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02606422, a NA study, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
61 participants
Enrollment target

Study Summary

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g. language) not attributable to motor or sensory loss, without impediment of social or occupational function. MCI can be an early sign of neurodegenerative disease, or can be due to normal aging. When language is the prominent affected domain in MCI, the person may later meet criteria for PPA or may progress to the clinical syndrome of Alzheimer's dementia. Spelling, naming, and working memory (e.g. repetition) are among the language abilities affected early in the course of PPA or language-centered MCI, and different variants have distinct deficits in these domains. This research project investigates the behavioral and neuromodulatory effects of high definition transcranial direct current stimulation (HD-tDCS) during language therapy in PPA participants over time. Anodal HD-tDCS targeting the left inferior frontal gyrus (IFG) administered in combination with language therapy is expected to be more beneficial when compared to language therapy alone. It will 1) improve language performance or decrease rate of decline, 2) have better-sustained effects at 2 weeks and 2 months post-treatment, and 3) produce generalization to untrained language items and some other cognitive functions. Resting-state fMRI, diffusion tensor imaging (DTI), and volumetric data are also collected to investigate changes in functional brain connectivity associated with HD-tDCS in individuals with PPA. A better understanding of the therapeutic and neuromodulatory mechanisms of HD-tDCS as an adjunct to language therapy in PPA may have a significant impact on the development of effective therapies for PPA and MCI, and may offer insight into ways of impeding neurodegeneration that may improve patients' quality of life, as well as extend their ability to work and manage their affairs.

Primary Outcome

The primary outcome measure was the absolute percentage change in the number of correct letters in the written response, compared to the target response in the trained word lists. This calculation reflects the change in accuracy between two timepoints. For letter accuracy scoring, a rule-based system was used where each letter was assigned one point if correct. Points were deducted for errors such as deletions, additions, substitutions, transpositions, or movements of letters. A second reviewer

Interventions

  • DEVICE Active HD-tDCS plus Speech-Language Therapy
  • DEVICE Sham plus Speech-Language Therapy

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2013-04
Est. Completion 2023-08-11
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT02606422 record still lists

NCT02606422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Active HD-tDCS plus Speech-Language Therapy is the first listed.

NCT02606422 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02606422 about?

NCT02606422 is a clinical study titled "tDCS Intervention in Primary Progressive Aphasia". Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g. language) not attributable to motor or sensory loss, without impediment of social o...

What is the current status of trial NCT02606422?

This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2013-04. Estimated completion is 2023-08-11.

What interventions are being tested in trial NCT02606422?

The interventions under investigation include: Active HD-tDCS plus Speech-Language Therapy (DEVICE), Sham plus Speech-Language Therapy (DEVICE).

Who is sponsoring clinical trial NCT02606422?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02606422's enrollment target sits among peer trials

61 1164th of 2000 higher than 837 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02606422, the US trial registry maintained by the National Library of Medicine. NCT02606422 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.